Actively Recruiting
Administering NMT to Reestablish Infant Nasal Microbiome Diversity Following Intranasal Mupirocin Treatment
Led by Johns Hopkins University · Updated on 2025-09-04
175
Participants Needed
1
Research Sites
122 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This protocol aims to evaluate how NMT affects pediatric nasal microbiome diversity following intranasal mupirocin treatment
CONDITIONS
Official Title
Administering NMT to Reestablish Infant Nasal Microbiome Diversity Following Intranasal Mupirocin Treatment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Child has had a prior nasal surveillance culture grow Staphylococcus aureus
- Child is younger than 18 years of age
- Child completed intranasal mupirocin treatment for S. aureus nasal colonization at least two days before transplant
- Child has anticipated hospital stay longer than 3 days after mupirocin treatment
- Infant is older than 25 weeks gestation unless older than 2 months chronological age
- Donor can provide informed consent
- Donor has a relationship with the child outside the hospital
You will not qualify if you...
- Child is a ward of the State
- Child has or is suspected of having immunodeficiency
- Child cannot have nasal swabs collected (e.g., due to nasal packing)
- Donor had a positive COVID-19 test within the past 21 days
- Donor shows signs of respiratory illness (runny nose, congestion, fever, cough)
- Donor had close contact with someone with a respiratory viral infection in the last 7 days
- Donor tests positive for S. aureus nasal colonization or respiratory pathogens
- Donor cannot provide written informed consent
- Donor cannot be present at the bedside for intervention
- Donor has chronic sinusitis, cystic fibrosis, or multi-drug resistant organism infection
- Donor cannot or will not complete the donor questionnaire or has positive responses
- Donor has smoked within the last month
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Johns Hopkins University
Baltimore, Maryland, United States, 21287
Actively Recruiting
Research Team
D
Danielle Koontz, Research Manager
CONTACT
S
Slade Decker, Senior Research Coordinator
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here